New chemotherapy regimens and biomarkers for Chagas disease
恰加斯病的新化疗方案和生物标志物
基本信息
- 批准号:9980275
- 负责人:
- 金额:$ 124.86万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-08-17 至 2023-07-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAdultAdverse drug eventAdverse eventAffectAftercareAgeAnimalsAntibodiesAntigensAntioxidantsAntiparasitic AgentsAppearanceBenznidazoleBiological MarkersBloodCardiomyopathiesChagas DiseaseChemotherapy-Oncologic ProcedureChildChronicChronic PhaseClassificationClinicalClinical ResearchClinical TrialsClinical Trials DesignCountryDataDetectionDiseaseDoseDrug CombinationsDrug KineticsEvaluationFailureFrequenciesGoldHeartHeat-Shock Proteins 70InfantInfectionInflammatoryLatin AmericaLyticMeasuresNifurtimoxOxidative StressParasitemiaParasitesPatientsPeptide antibodiesPeptidesPeripheralPharmaceutical PreparationsPharmacotherapyPhasePlayPolysaccharidesPopulationPrognostic MarkerProteinsPublic HealthReactionRecombinant ProteinsRegimenReportingResearch DesignRoleSafetySerologic testsSerologicalSerumSymptomsTechniquesTestingTherapeuticThrombophiliaTreatment ProtocolsTreatment outcomeTrypanosoma cruziTumor stageaptamerchemotherapychronic infectioncohortdrug efficacyearly detection biomarkersexperiencefollow-upimprovednovelnovel diagnosticsprogression markerresponseseroconversionstandard caresuccesstherapy outcometooltreatment durationtreatment response
项目摘要
ABSTRACT
Chagas disease is caused by the parasite, Trypanosoma cruzi, and affects millions of people in Latin America.
Lately, Chagas disease has become an emerging worldwide public health issue due to globalization. Chagas
disease has two phases: an initial acute phase, usually with nonspecific symptoms or asymptomatic, and a
lifelong chronic phase, which is clinically silent or indeterminate in 60-70% of patients. However, 30-40% of
chronic patients will eventually develop heart and/or digestive complications. Currently, the only approved
drugs for treating Chagas disease are benznidazole (BZN) and nifurtimox (NFX). The efficacy of these drugs is
variable and depends on the disease stage, drug dose, age of patients, and infecting T. cruzi strain(s).
Treatment in the acute phase is effective with both drugs. However, the efficacy of these drugs in adults with
chronic, long-established infections is significantly lower and variable. Moreover, the high rate of adverse
events of these drugs has hampered their regular clinical use, thus <1% of patients are being treated. In this
project, we propose to test four new dosing regimens of BZN and NFX. Our first hypothesis is that a lower
frequency of BZN and NFX dosing, with standard or extended treatment duration, might have the same or
better efficacy than the standard treatment regimens with these drugs, with fewer adverse events. Here, we
plan to analyze current and novel host- and parasite-derived BMKs that have shown promising results in pilot,
full clinical trials or in animal studies, providing a measure of disease state and cure. Thus, our second
hypothesis is that in those patients that respond to BZN or NFX treatment the serum levels of one or more
proposed BMKs will be significantly reduced or become negative within three years post-treatment. To test
these two hypotheses, we propose two specific aims: Specific Aim 1: To determine the safety and efficacy of
extended benznidazole or nifurtimox treatment regimens with lower dosing frequency. Specific Aim 2: To
evaluate host- and parasite-derived biomarkers for the follow-up of Chagas disease chemotherapy. The
information gained in this project would also allow for better-designed clinical trials with previously proposed
drug combinations, in which BZN and NFX would play a central role.
摘要
恰加斯病是由克氏锥虫寄生虫引起的,在拉丁美洲影响着数百万人。
最近,由于全球化,恰加斯病已经成为一个新兴的世界性公共卫生问题。查加斯
疾病有两个阶段:最初的急性期,通常有非特异性症状或无症状,以及
终生慢性期,60%-70%的患者临床上无症状或不确定。然而,30%-40%的
慢性患者最终会出现心脏和/或消化并发症。目前,唯一获批的
治疗恰加斯病的药物是苯硝唑(BZN)和硝呋莫司(NFX)。这些药物的疗效是
可变的,取决于疾病阶段、药物剂量、患者年龄和感染克鲁兹旋毛虫菌株(S)。
急性期的治疗对这两种药物都有效。然而,这些药物在成年人中的疗效
长期存在的慢性感染率明显较低且多变。此外,较高的不良反应发生率
这些药物的事件阻碍了它们的正常临床使用,因此1%的患者正在接受治疗。在这
在该项目中,我们建议测试四种新的BZN和NFX给药方案。我们的第一个假设是较低的
标准疗程或延长疗程的BZN和NFX剂量的频率可能相同或
与使用这些药物的标准治疗方案相比,疗效更好,不良事件更少。在这里,我们
计划分析当前和新的宿主和寄生虫来源的BMK,这些BMK在试点中显示出有希望的结果,
完整的临床试验或动物研究,提供疾病状态和治愈的衡量标准。因此,我们的第二个
假说是,在那些对BZN或NFX治疗有反应的患者中,血清中一种或多种
建议的BMK将在治疗后三年内显著减少或转为阴性。为了测试
这两个假设,我们提出了两个具体目标:具体目标1:确定的安全性和有效性
扩大的苯硝唑或硝呋莫司治疗方案的剂量频率较低。具体目标2:
评估宿主和寄生虫来源的生物标记物用于查加斯病化疗的随访。这个
从这个项目中获得的信息还将使先前提议的更好地设计临床试验成为可能
药物组合,其中BZN和NFX将发挥核心作用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
IGOR C ALMEIDA其他文献
IGOR C ALMEIDA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('IGOR C ALMEIDA', 18)}}的其他基金
New chemotherapy regimens and biomarkers for Chagas disease
恰加斯病的新化疗方案和生物标志物
- 批准号:
10219078 - 财政年份:2018
- 资助金额:
$ 124.86万 - 项目类别:
New chemotherapy regimens and biomarkers for Chagas disease
恰加斯病的新化疗方案和生物标志物
- 批准号:
9764253 - 财政年份:2018
- 资助金额:
$ 124.86万 - 项目类别:
New chemotherapy regimens and biomarkers for Chagas disease
恰加斯病的新化疗方案和生物标志物
- 批准号:
10469327 - 财政年份:2018
- 资助金额:
$ 124.86万 - 项目类别:
New chemotherapy regimens and biomarkers for Chagas disease
恰加斯病的新化疗方案和生物标志物
- 批准号:
9484015 - 财政年份:2018
- 资助金额:
$ 124.86万 - 项目类别:
New chemotherapy regimens and biomarkers for Chagas disease
恰加斯病的新化疗方案和生物标志物
- 批准号:
10557245 - 财政年份:2017
- 资助金额:
$ 124.86万 - 项目类别:
Molecular Composition and Function of Trypanosoma cruzi Shed Vesicles
克氏锥虫脱落囊泡的分子组成和功能
- 批准号:
8147543 - 财政年份:2010
- 资助金额:
$ 124.86万 - 项目类别:
Identification and Validation of Novel Antigenic Targets in Trypanosoma cruzi
克氏锥虫新抗原靶标的鉴定和验证
- 批准号:
7858084 - 财政年份:2009
- 资助金额:
$ 124.86万 - 项目类别:
BIOMOLECULE CHARACTERIZATION AND SEPARATION CORE FACILITY
生物分子表征和分离核心设施
- 批准号:
7959146 - 财政年份:2009
- 资助金额:
$ 124.86万 - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 124.86万 - 项目类别:
Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 124.86万 - 项目类别:
Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 124.86万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 124.86万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 124.86万 - 项目类别:
Standard Grant
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 124.86万 - 项目类别:
Discovery Early Career Researcher Award
RUI: Evaluation of Neurotrophic-Like properties of Spaetzle-Toll Signaling in the Developing and Adult Cricket CNS
RUI:评估发育中和成年蟋蟀中枢神经系统中 Spaetzle-Toll 信号传导的神经营养样特性
- 批准号:
2230829 - 财政年份:2023
- 资助金额:
$ 124.86万 - 项目类别:
Standard Grant
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 124.86万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 124.86万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 124.86万 - 项目类别:
Grant-in-Aid for Scientific Research (C)